Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Mission Therapeutics

This page shows the latest Mission Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Kriya Therapeutics raises $100m to further develop gene therapies with ‘broader applications’

Kriya Therapeutics raises $100m to further develop gene therapies with ‘broader applications’

US-based biotech company Kriya Therapeutics has raised $100m in Series B financing to further develop its core technology platforms, aiming to advance lower cost gene therapies with broader applications. ... However, the field has been constrained by

Latest news

  • Halozyme faces late-stage pancreatic cancer drug failure, cuts 55% of jobs Halozyme faces late-stage pancreatic cancer drug failure, cuts 55% of jobs

    Halozyme Therapeutics has stopped its pivotal phase 3 study investigating its lead pancreatic cancer drug – and has announced a major restructuring of its workforce that has resulted in a 55% reduction ... Our mission now is to transition our strategy

  • Biomedical Catalyst funding 'must continue', says BIA Biomedical Catalyst funding 'must continue', says BIA

    macular degeneration (AMD), almost £3m for a Kings College London research team developing a T cell therapy for Crohn's disease and £1.9m for Cambridge start-up MISSION Therapeutics to

  • GSK forms alliance with Epizyme

    The therapeutics would work by controlling the pathways of gene expression that contribute to diseases. ... Dr Robert Gould, CEO and president of Epizyme, said: "Epizyme's mission is to develop personalised therapeutics for genetically-defined patients

More from news
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Can protein degraders unlock ‘undruggable’ drug targets? Can protein degraders unlock ‘undruggable’ drug targets?

    1 trial of its lead candidate ARV-110 in prostate cancer earlier this year, ahead of rival biotechs such as C4 Therapeutics and Kymera Therapeutics as well as big pharma firms ... Other approaches are also in early-stage testing. Deubiquitylating (DUB)

  • 25 Women Leaders in UK Healthcare 25 Women Leaders in UK Healthcare

    The new wave of healthcare has to start to bring diagnostics, devices and therapeutics together. ... Before she joined Crescendo, she held industry and corporate finance roles with private and listed SMEs, including PsiOxus Therapeutics, MISSION

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Dr Colin Goddard appointed chairman at Mission Therapeutics Dr Colin Goddard appointed chairman at Mission Therapeutics

    Mission Therapeutics has appointed Dr Colin Goddard as its non-executive chairman, a role he will take up on January 1. ... Meanwhile, Mission Therapeutics' current chairman Dr Michael Moore will continue to sit on the firm's board and move into the

  • Crescendo Biologics appoints CFO Crescendo Biologics appoints CFO

    She joins from PsiOxus Therapeutics where she served as chief financial officer, and has also held a number of positions at Cytomyx Holdings, OrthoMimetics, and Mission Therapeutics. ... ambitious plans to create a high value pipeline of differentiated

  • Mission Therapeutics appoints new chief financial officer Mission Therapeutics appoints new chief financial officer

    David Luther joins with 25 years healthcare and pharmaceutical experience. Cambridge, UK-based Mission Therapeutics has appointed David Luther as chief financial officer. ... development. Dr Anker Lundemose, CEO of Mission Therapeutics, said: “David's

  • MISSION appoints Paul Wallace as chief business officer MISSION appoints Paul Wallace as chief business officer

    Cancer biotech MISSION Therapeutics has named Paul Wallace as chief business officer. ... The diversity of assets created is testimony to the rigour of MISSION's screening platform in this critically important, but hitherto difficult, area of drug

More from appointments
Approximately 1 fully matching, plus 3 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >300 healthcare communications professionals,...

Latest intelligence

Rare diseases: not so rare after all
The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...

Quick links